PPD, Inc. announced it has reached an agreement to acquire Excel PharmaStudies, Inc., a China-based CRO specializing in Phase II-IV clinical trials. Founded in 2000, Excel has offices in 15 China cities and over 300 employees. It has worked with more than 120 pharmas and biotech companies. PPD said the purchase will add capacity and expertise in China, while also increasing its employee count and client base in the Asia Pacific region. Financial terms of the acquisition were not disclosed. More details...

Stock Symbol: (NSDQ: PPDI)